X

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary) ; Diphenhydramine; Methylprednisolone; Paracetamol
Indications Systemic lupus erythematosus
Focus Registrational; Therapeutic Use
Acronyms ALLEGORY
Sponsors Roche

Most Recent Events

17 Oct 2023 Planned End Date changed from 13 Jun 2026 to 30 Nov 2027.
14 Jun 2023 Planned number of patients changed from 200 to 300.
25 Feb 2022 Planned End Date changed from 13 Nov 2027 to 13 Jun 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com